Abstract:Background Anti-tumor necrosis factor alpha (TNF- α ) therapy has made a significant impact on treating psoriasis. Despite these agents being designed to block TNF- α activity, their mechanism of action in the remission of psoriasis is still not fully understood at the molecular level. Results To better understand the molecular mechanisms of Anti-TNF- α therapy, we analysed the global gene expression profile (using mRNA microarray) in peripheral blood mononuclear cells (PBMCs) that were collected from 6 psoriasis patients before and 12 weeks after the treatment of etanercept. First, we identified 176 differentially expressed genes (DEGs) before and after treatment by using paired t-test. Then, we constructed the gene co-expression modules by weighted correlation network analysis (WGCNA), and 22 co-expression modules were found to be significantly correlated with treatment response. Of these 176 DEGs, 79 DEGs (M_DEGs) were the members of these 22 co-expression modules. Of the 287 GO functional processes and pathways that were enriched for these 79 M_DEGs, we identified 30 pathways whose overall gene expression activities were significantly correlated with treatment response. Of the original 176 DEGs, 19 (GO_DEGs) were found to be the members of these 30 pathways, whose expression profiles showed clear discrimination before and after treatment. As expected, of the biological processes and functionalities implicated by these 30 treatment response-related pathways, the inflammation and immune response was the top pathway in response to etanercept treatment, and some known TNF- α related pathways, such as molting cycle process, hair cycle process, skin epidermis development, regulation of hair follicle development, were implicated. Furthermore, additional novel pathways were also suggested, such as heparan sulfate proteoglycan metabolic process, vascular endothelial growth factor production, whose transcriptional regulation may mediate the response to etanercept treatment. Conclusion Through global gene expression analysis in PBMC of psoriasis patient and subsequent co-expression module based pathway analyses, we have identified a group of functionally coherent and differentially expressed genes (DEGs) and related pathways, which has not only provided new biological insight about the molecular mechanism of anti-TNF- α treatment, but also identified several genes whose expression profiles can be used as potential biomarkers for anti-TNF- α treatment response in psoriasis.

Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments

Anti-TNF- Αtreatment-Related Pathways and Biomarkers Revealed by Transcriptome Analysis in Chinese Psoriasis Patients

Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets

Exploring the Common Pathogenic Mechanisms of Psoriasis and Atopic Dermatitis: the Interaction Between SGK1 and TIGIT Signaling Pathways

Integrated bioinformatic analysis of key biomarkers and signalling pathways in psoriasis

The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment.

Pathogenesis, Multi-Omics Research, and Clinical Treatment of Psoriasis.

Exploration of the Potential Mechanism of the Common Differentially Expressed Genes in Psoriasis and Atopic Dermatitis

Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases

Psoriasis pathogenesis and the development of novel targeted immune therapies

Immune responses and therapeutic options in psoriasis

ULK1 Inhibition as a Targeted Therapeutic Strategy for Psoriasis by Regulating Keratinocytes and Their Crosstalk With Neutrophils

Tissue gene expression profiles and communication networks inform candidate blood biomarker identification in psoriasis and atopic dermatitis

New Treatment Addressing the Pathogenesis of Psoriasis

Role of co‐inhibitory molecules in the treatment of psoriasis (Review)

A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions

Epigenetic‐modifying therapies: An emerging avenue for the treatment of inflammatory skin diseases

Skin barrier-inflammatory pathway is a driver of the psoriasis-atopic dermatitis transition

Immunopathology and Immunotherapy of Inflammatory Skin Diseases

Natural Modulators Of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation

Advances in psoriasis research: From pathogenesis to therapeutics